FIELD: medicine.
SUBSTANCE: level of marker CD3, CD4 expression by peripheral lymphocytes is detected by indirect immunofluorescence assay using monoclonal antibodies in the patients with peptic ulcer (PU). If the CD3 value is 70.5-75.00%, and the CD4 value is 36.2-41.0%, the presence of mild clinical course of peptic ulcer is diagnosed; the CD3 value being 65.00-70.00% and the CD4 value being 33.5-36.0% show moderate clinical course of peptic ulcer, while the CD3 value 56.00-63.00% and the CD4 value 29.0-33.0% stands for severe clinical course of peptic ulcer.
EFFECT: method provides the well-timed detection of the severity of the clinical course of peptic ulcer, including in the first manifested disease.
3 ex, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DIAGNOSTIC TECHNIQUE FOR SEVERE CLINICAL COURSE IN GASTRIC ULCER | 2011 |
|
RU2455649C1 |
| METHOD OF TREATING Helicobacter pylori ASSOCIATED CHRONIC ULCEROUS DISEASE OF STOMACH AND DUODENUM | 2010 |
|
RU2416408C1 |
| METHOD FOR PREDICTING THE EXACERBATIONS OF GASTRODUODENAL ULCER ASSOCIATED WITH HELICOBACTER PYLORI | 2017 |
|
RU2664449C1 |
| METHOD FOR TREATING HELICOBACTER-ASSOCIATED CHRONIC DUODENAL ULCER | 2003 |
|
RU2252777C2 |
| METHOD FOR PREDICTION OF RISK OF HELICOBACTER PYLORI-NEGATIVE GASTRIC AND DUODENAL ULCER | 2023 |
|
RU2821471C1 |
| METHOD OF ERADICATION THERAPY SELECTION FOR ULCER PATIENTS ASSOCIATED WITH Helicobacter pylori | 2006 |
|
RU2325164C1 |
| METHOD FOR PREDICTING RISK OF DEVELOPING GASTRIC AND DUODENAL ULCERS IN WOMEN BASED ON MOLECULAR GENETIC TESTING | 2023 |
|
RU2811577C1 |
| METHOD FOR EVALUATING OZONE THERAPY EFFECTIVENESS IN PATIENTS POSSESSING CHELICOBACTER DISEASE | 1999 |
|
RU2155344C1 |
| DIAGNOSTIC TECHNIQUE FOR DEGREE OF ACTIVITY OF ANTRAL HELICOBACTER-ASSOCIATED GASTRITIS IN PATIENTS WITH BRONCHIAL ASTHMA | 2009 |
|
RU2394499C1 |
| METHOD OF IMMUNODIAGNOSIS OF GASTRODUODENAL ZONE DISEASES | 2017 |
|
RU2677228C1 |
